Skip to main content

Table 7 Multivariable analysis of prognostic factors for III-IVb NPC patients treated with PF regimen

From: Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein–Barr virus DNA level

 

HR (95%CI)

P-value value

Progression-free survival

 Age (y) (≥ 45 vs. <  45)

1.319(0.839–2.074)

0.231

 Gender (F vs. M)

1.496(0.844–2.651)

0.168

 T category (3–4 vs. 1–2)

1.556(0.755–3.208)

0.231

 N category (2–3 vs. 0–1)

1.736(0.897–3.361)

0.101

 Overall stage (IVa-b vs. III)

1.711(1.047–2.796)

0.032

 EBV DNA (< 1500 vs. ≥1500)

2.327(1.223–4.427)

0.010

 RT method (IMRT vs. 2D-RT)

1.159(0.910–1.477)

0.232

Overall survival

 Age (y) (≥ 45 vs. <  45)

2.067(0.986–4.33)

0.054

 Gender (F vs. M)

0.710(0.329–1.535)

0.384

 T category (3–4 vs. 1–2)

0.921(0.335–2.533)

0.874

 N category (2–3 vs. 0–1)

1.150(0.446–2.966)

0.772

 Overall stage (IVa-b vs. III)

1.998(0.911–4.384)

0.084

 EBV DNA (< 1500 vs. ≥1500)

5.091(1.209–21.430)

0.027

 RT method (IMRT vs. 2D-RT)

0.875(0.660–1.290)

0.244

Locoregional relapse-free survival

 Age (y) (≥ 45 vs. <  45)

1.035(0.500–2.140)

0.927

 Gender (F vs. M)

0.866(0.378–1.986)

0.734

 T category (3–4 vs. 1–2)

1.136(0.371–3.479)

0.823

 N category (2–3 vs. 0–1)

0.812(0.334–1.975)

0.646

 Overall stage (IVa-b vs. III)

2.002(0.890–4.502)

0.093

 EBV DNA (< 1500 vs. ≥1500)

3.431(1.032–11.400)

0.044

 RT method (IMRT vs. 2D-RT)

1.213(0.818–1.801)

0.337

Distant metastasis-free survival

 Age (y) (≥ 45 vs. <  45)

0.913(0.531–1.571)

0.742

 Gender (F vs. M)

2.125(0.993–4.548)

0.052

 T category (3–4 vs. 1–2)

2.041(0.791–5.265)

0.140

 N category (2–3 vs. 0–1)

2.353(0.984–5.626)

0.054

 Overall stage (IVa-b vs. III)

1.619(0.902–2.905)

0.107

 EBV DNA (< 1500 vs. ≥1500)

1.912(0.927–3.946)

0.079

 RT method (IMRT vs. 2D-RT)

1.242(0.919–1.679)

0.158

  1. A Cox proportional hazards regression model was used to detect variables individually without adjustment. All variables were transformed into categorical variables. HRs were calculated for age (years) (≥45 vs. < 45), sex (female vs. male), T stage (T3–4 vs. T1–2), N stage (N2–3 vs. N0–1), plasma EBV DNA before the first treatment (≥1500 copies/ml vs. < 1500 copies/ml), overall stage (IVa-b vs. III), and RT method (IMRT vs. 2D-RT)
  2. Abbreviations: CI Confidence interval, EBV Epstein–Barr virus, PF Cisplatin with fluorouracil
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us